Zydus Gets USFDA Final Nod for Azithromycin for Oral Suspension | CORPORATE ETHOS

Zydus Gets USFDA Final Nod for Azithromycin for Oral Suspension

By: | August 1, 2018
Zydus-Cadila

Aug 1: Drug maker Zydus Cadila on Wednesday said that it has received the final approval from the USFDA to market its Azithromycin for Oral Suspension USP (US RLD – Zithromax), 100 mg/5 mL and 200 mg/5 mL.

According to the company, this medication contains Azithromycin, a macrolide antibiotic that fights bacteria.

“It is used to treat different types of bacterial infections such as respiratory infections, skin infections, ear infections and sexually transmitted diseases. This medication will not work for Viral infections such as common cold, flu etc,” the company said.

“The drug will be manufactured at the group’s formulations manufacturing facility at Baddi,” it added.

Based in Ahmedabad, the Pankaj R Patel promoted Zydus Cadila Group is a research driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The group now has 213 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.